1. US Food and Drug Administration. Medical Review of NDA 202799. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2012/202799Orig1s000MedR.pdf
2. Peptides for cell-selective drug delivery;Svensen;Trends Pharmacol. Sci.,2012
3. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells;Curnis;Cancer Res.,2002
4. Oritavancin: an investigational lipoglycopeptide antibiotic;Karaoui;Am. J. Health. Syst. Pharm.,2013
5. The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians;Shore;Ther. Adv. Chronic Dis.,2011